sehcat 370kbq capsule,hard
ge healthcare buchler gmbh & co kg (0000003641) gieselweg 1, braunschweig, 38110 - tauroselcholic acid - capsule,hard - 370kbq - tauroselcholic acid (0075018712) 11,9ug
sehcat 370kbq/cap caps
ge healthcare a.e. - selenium (75 se) tauroselcholic acid - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - 370kbq/cap - ΡΑΔΙΟΦΑΡΜΑΚΕΥΤΙΚΟ
sehcat tm 37kbq/cap caps
ΜΠΑΚΑΚΟΣ Π. Α.Ε. - selenium (75 se) tauroselcholic acid - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - 37kbq/cap - ΡΑΔΙΟΦΑΡΜΑΚΕΥΤΙΚΟ
sehcat (ραδιοφαρμακο) caps 370kbq/cap
ge healthcare limited, amersham, buckinghamshire, u.k. the grove centre, white lion road, amersham, - tauroselcholic acid - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 370kbq/cap - tauroselcholic acid 370kbq - selenium (75se) tauroselcholic acid
sehcat® caps 370kbq/cap
tauroselcholic acid - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 370kbq/cap - tauroselcholic acid 370kbq - selenium (75se) tauroselcholic acid
jayempi
nova laboratories ireland limited - azathioprine - Απόρριψη μοσχεύματος - Ανοσοκατασταλτικά - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.
otezla
amgen europe bv - apremilast - arthritis, psoriatic; psoriasis - Ανοσοκατασταλτικά - Ψωριασική arthritisotezla, μόνο του ή σε συνδυασμό με την τροποποιητική της Νόσου Αντιρευματικά Φάρμακα (dmards), ενδείκνυται για τη θεραπεία της ενεργή ψωριασική αρθρίτιδα (psa) σε ενήλικες ασθενείς οι οποίοι είχαν ανεπαρκή ανταπόκριση ή έχουν δυσανεξία σε προηγούμενη θεραπεία με dmard. psoriasisotezla ενδείκνυται για τη θεραπεία της μέτριας έως σοβαρή χρόνια ψωρίαση κατά πλάκας σε ενήλικες ασθενείς που δεν ανταποκρίθηκαν ή παρουσιάζουν αντενδείξεις ή έχουν δυσανεξία σε άλλες συστηματικές θεραπεία, συμπεριλαμβανομένων της κυκλοσπορίνης, της μεθοτρεξάτης ή ψωραλένιο και υπεριώδης-φως (puva).
quofenix
a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin αντιμονιακή - Κοινοτικές Συγκολλημένες Λοιμώξεις - Αντιβακτηριακά για συστηματική χρήση, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 και 5. Πρέπει να ληφθούν υπόψη οι επίσημες οδηγίες για την κατάλληλη χρήση των αντιβακτηριακών παραγόντων.
sporilen 25mg/cap καψακιο, μaλακο
libytec ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε. Δ.Τ. libytec a.e. (0000009281) Λ. Βουλιαγμένης 24, Ελληνικό, 16777 - ciclosporin - ΚΑΨΑΚΙΟ, ΜaΛΑΚΟ - 25mg/cap - 0059865133 ciclosporin 25.000000 mg - ciclosporin
sporilen soft.caps 50mg/cap
libytec ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε. Δ.Τ. libytec a.e. Λ. Βουλιαγμένης 24, 16777 Ελληνικό 210.9609960 - ciclosporin - soft.caps (ΚΑΨΑΚΙΟ, ΜaΛΑΚΟ) - 50mg/cap - ciclosporin 50mg - ciclosporin